(Q42986419)

English

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype

scientific article published on March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

author name string

Norio Itokawa

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Masanori Atsukawa

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Akihito Tsubota

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Chisa Kondo

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Satomi Hashimoto

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Takeshi Fukuda

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoko Matsushita

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hideko Kidokoro

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tamaki Kobayashi

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshiyuki Narahara

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Katsuhisa Nakatsuka

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hidenori Kanazawa

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Katsuhiko Iwakiri

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Choitsu Sakamoto

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

443-449

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Antiviral therapy for chronic hepatitis C: past, present, and future

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

New therapeutic approaches to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon alpha/beta receptor: effects on JAK-STAT activation and receptor down-regulation

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12039

21 January 2018

Identifiers

10.1111/JGH.12039

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42986419&oldid=1975875784"